Libratus

NVAX- Dark horse in the vaccine race

做多
NASDAQ:NVAX   Novavax, Inc.
No one can predict the result of NVAX's phase 3 trial. However, I don't count out any potential winners in the vaccine race even though now it seems very likely that NVAX won't be the first one to distribute vaccines at massive scale.

That being said, as long as the result of phase 3 trial isn't a complete failure, I think the crowd frenzy will keep pushing NVAX's price up.

To be on the safe side, I would market buy 33% of my overall position and limit buy the remaining in the demand zone.

Just my opinion. Not the investment advice.


免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。